Archer-Daniels-Midland Co (ADM) Stock News

ADMA Biologics faces a class action securities fraud lawsuit alleging the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth. A March 2026 report revealed ADMA induced distributors to stock excess inventory through rebates and extended payment terms, resulting in a 29.1% stock price decline. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026, with an August 10, 2026 deadline to file a lead plaintiff motion.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

Rosen Law Firm reminds investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of the August 10, 2026 deadline to join a securities class action lawsuit. The firm alleges that ADMA made false statements regarding undisclosed related-party transactions, channel stuffing practices, inadequate internal controls, and misleading revenue representations during the period from August 9, 2024 to March 25, 2026.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

A class action lawsuit has been filed against ADMA Biologics for alleged securities fraud. Culper Research published a report claiming the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The allegations led to a 29.1% stock price decline on March 25, 2026. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file a lead plaintiff motion by August 10, 2026.

ADMA Biologics faces a securities fraud class action lawsuit after Culper Research alleged the company engaged in channel stuffing to artificially inflate 2025 revenue growth from -3% to reported +20%. The allegations triggered a 29% stock decline, with the largest single-day drop of 16.6% on March 24, 2026. Investors have until August 10, 2026, to request lead plaintiff status.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth was artificially inflated through extended payment terms, with actual revenue declining 3% in 2025. The stock fell over 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. Investors who purchased ADMA securities during this period are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.

ADMA Biologics faces a federal securities class action lawsuit alleging the company made false statements about its financial performance through channel stuffing schemes and undisclosed related party transactions. An investigative report revealed ADMA artificially inflated 2025 revenue growth from -3% to +20% by inducing distributors to overstock products with rebates and extended payment terms. The stock declined 29% following the report's publication on March 24, 2026. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with a deadline of August 10, 2026 to seek lead plaintiff status.

Rosen Law Firm announces securities class action lawsuits against ADMA Biologics (NASDAQ: ADMA) and Graphic Packaging Holding Company (NYSE: GPK). ADMA investors who purchased securities between August 9, 2024 and March 25, 2026 must act by August 10, 2026 deadline. The lawsuit alleges ADMA engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls. GPK investors with losses exceeding $100K have a July 6, 2026 deadline.

Rosen Law Firm is pursuing securities class action lawsuits against ADMA Biologics, Nano-X Imaging, and DNOW Inc. on behalf of investors. The ADMA case alleges undisclosed related party transactions, channel stuffing, and inadequate internal controls during the August 2024 to March 2026 period, with an August 10, 2026 deadline for lead plaintiff claims.

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca, Inc. The lawsuits allege that defendants made materially false statements or failed to disclose material facts regarding business risks and practices. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the respective deadlines in August 2026.

A class action securities lawsuit has been filed against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. The case is pending in the U.S. District Court for the District of New Jersey, with an August 10, 2026 deadline for investors to request lead plaintiff status.

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits. BitGo Holdings faces allegations of false statements regarding digital asset price risks (deadline: August 7, 2026). ADMA Biologics is accused of misstatements about business practices between August 2024 and March 2026 (deadline: August 10, 2026). Erasca, Inc. faces allegations of false statements regarding ERAS-0015 between January 2025 and April 2026 (deadline: August 10, 2026).

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an important August 10, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The complaint alleges the company engaged in channel stuffing, undisclosed related party transactions, and lacked adequate internal controls. The stock dropped 29.1% following a Culper Research report exposing these practices. Investors who purchased securities between August 9, 2024 and March 25, 2026 can seek lead plaintiff status by August 10, 2026.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly engaging in channel stuffing, undisclosed related party transactions, and lacking adequate internal controls. Following a March 2026 short seller report by Culper Research alleging revenue manipulation through excess product stocking with extended payment terms, ADMA shares declined approximately 46% over three trading days. The lawsuit covers investors who purchased securities between August 9, 2024 and March 25, 2026.

Rosen Law Firm has filed securities class action lawsuits against ADMA Biologics, Roblox Corporation, and Phreesia, Inc., alleging materially false statements and undisclosed practices. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for ADMA Biologics and similar deadlines for other cases. Investors who purchased securities during specified class periods may be eligible for compensation.

ADMA Biologics faces a securities class action lawsuit alleging failure to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. Investors with losses exceeding $100,000 have until August 10, 2026 to file lead plaintiff applications for securities purchased between August 9, 2024 and March 25, 2026.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth, engaging in channel stuffing, and failing to disclose related party transactions. Following a critical report by Culper Research on March 24, 2026, ADMA's stock declined over 16%, and subsequently fell another 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses between August 9, 2024 and March 25, 2026 can seek appointment as lead plaintiff by August 10, 2026.

A class action securities lawsuit has been filed against ADMA Biologics, Inc. for allegedly failing to disclose material information including undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with an August 10, 2026 deadline to request lead plaintiff status.

Pomerantz LLP has filed class action lawsuits against ADMA Biologics, GeneDx Holdings, and Helen of Troy Limited, alleging securities fraud and unlawful business practices. The lawsuit against ADMA was triggered by a Culper Research report alleging channel stuffing schemes, which caused the stock to fall 16.63% on March 24, 2026, followed by a 13.91% decline after a Cantor Fitzgerald downgrade on March 26, 2026. Investors have until August 10, 2026, to request Lead Plaintiff status.

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The stock dropped 29.1% after Culper Research published a report alleging channel stuffing and undisclosed related party transactions. The deadline to seek lead plaintiff status is August 10, 2026.

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth, engaging in channel stuffing, failing to disclose related party transactions, and lacking adequate internal controls. A short-seller report triggered a 16% stock decline, followed by a 13% drop after a downgrade from Cantor Fitzgerald.

The Schall Law Firm is seeking investors to join a class action lawsuit against ADMA Biologics, Inc. for securities fraud. The company allegedly made false and misleading statements, engaged in undisclosed related party transactions, used channel stuffing to inflate revenue, and failed to maintain proper internal controls during the period from August 9, 2024 to March 25, 2026.